Table 1.
Subject baseline characteristics
| Controls | Patients with IPF | ||
|---|---|---|---|
| Serum | BALF | ||
| Subjects, n | 90 | 79 | 57 |
| Age, years | 53.8 ± 3.6 | 67.4 ± 8.8* | 66.5 ± 8.8* |
| Sex, Male/Female | 77/13 | 70/9 | 53/4 |
| Smoking history, pack-years | 16.8 ± 18.3 | 39.4 ± 28.5* | 38.3 ± 25.0* |
| FVC, % predicted | 109.3 ± 16.2 | 78.7 ± 18.2* | 78.7 ± 19.2* |
| DLco, % predicteda | – | 50.2 ± 16.3 | 51.2 ± 16.1 |
| BALF total cell, × 104/ml | – | – | 21.9 ± 16.0 |
| BALF macrophage, % | – | – | 83.4 ± 11.4 |
| BALF lymphocyte, % | – | – | 11.4 ± 10.3 |
| BALF neutrophil, % | – | – | 3.3 ± 3.3 |
| BALF eosinophil, % | – | – | 1.9 ± 2.6 |
*vs. Control, p < 0.05 Mann-Whitney U-test
aDLco was measured in 73 of 79 IPF patients with serum sample and 55 of 57 patients with BALF sample, respectively
Values are mean ± SD unless stated otherwise
BALF bronchoalveolar lavage fluid, DLco diffusing capacity for carbon monoxide, IPF idiopathic pulmonary fibrosis, FVC forced vital capacity